☰

Gary Dewayne Probst - Publications

Affiliations: 
1994-2001 Chemistry Stanford University, Palo Alto, CA 
Tree Info Similar researchers PubMed Report error

10/38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Franzini M, Ye XM, Adler M, Aubele DL, Garofalo AW, Gauby S, Goldbach E, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong A, Ren Z. Triazolopyridazine LRRK2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 1967-73. PMID 23454015 DOI: 10.1016/J.Bmcl.2013.02.043  0.595
2013 Garofalo AW, Adler M, Aubele DL, Brigham EF, Chian D, Franzini M, Goldbach E, Kwong GT, Motter R, Probst GD, Quinn KP, Ruslim L, Sham HL, Tam D, Tanaka P, et al. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 1974-7. PMID 23453068 DOI: 10.1016/J.Bmcl.2013.02.041  0.586
2013 Garofalo AW, Adler M, Aubele DL, Bowers S, Franzini M, Goldbach E, Lorentzen C, Neitz RJ, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong AP, Ye XM, et al. Novel cinnoline-based inhibitors of LRRK2 kinase activity. Bioorganic & Medicinal Chemistry Letters. 23: 71-4. PMID 23219325 DOI: 10.1016/J.Bmcl.2012.11.021  0.601
2011 Bowers S, Truong AP, Neitz RJ, Neitzel M, Probst GD, Hom RK, Peterson B, Galemmo RA, Konradi AW, Sham HL, Tóth G, Pan H, Yao N, Artis DR, Brigham EF, et al. Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor. Bioorganic & Medicinal Chemistry Letters. 21: 1838-43. PMID 21316234 DOI: 10.1016/j.bmcl.2011.01.046  0.355
2011 Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, et al. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorganic & Medicinal Chemistry Letters. 21: 315-9. PMID 21112785 DOI: 10.1016/j.bmcl.2010.11.010  0.305
2010 Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, Tóth G, Pan H, Yao N, et al. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorganic & Medicinal Chemistry Letters. 20: 7303-7. PMID 21071223 DOI: 10.1016/j.bmcl.2010.10.066  0.322
2010 Kasibhatla SR, Bookser BC, Probst G, Appleman JR, Erion MD. ChemInform Abstract: AMP Deaminase Inhibitors. Part 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues. Cheminform. 31: no-no. DOI: 10.1002/chin.200031218  0.303
2010 TROST BM, PROBST GD, SCHOOP A. ChemInform Abstract: Ruthenium-Catalyzed Alder Ene Type Reactions. A Formal Synthesis of Alternaric Acid. Cheminform. 30: no-no. DOI: 10.1002/chin.199903227  0.41
2004 Trost BM, Yang H, Probst GD. A formal synthesis of (-)-mycalamide A. Journal of the American Chemical Society. 126: 48-9. PMID 14709053 DOI: 10.1021/Ja038787R  0.467
1998 Trost BM, Probst GD, Schoop A. Ruthenium-catalyzed alder ene type reactions. A formal synthesis of alternaric acid Journal of the American Chemical Society. 120: 9228-9236. DOI: 10.1021/Ja981540N  0.521
Low-probability matches (unlikely to be authored by this person)
2013 Ng RA, Sun M, Bowers S, Hom RK, Probst GD, John V, Fang LY, Maillard M, Gailunas A, Brogley L, Neitz RJ, Tung JS, Pleiss MA, Konradi AW, Sham HL, et al. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 4674-9. PMID 23856050 DOI: 10.1016/j.bmcl.2013.06.006  0.292
2010 Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, et al. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorganic & Medicinal Chemistry Letters. 20: 6034-9. PMID 20822903 DOI: 10.1016/j.bmcl.2010.08.070  0.28
1998 Kasibhatla SR, Bookser BC, Appleman JR, Probst G, Xiao W, Fujitaki JM, Erion MD. Design, synthesis, and structure-activity relationships of the first highly potent, selective, and bioavailable adenosine 5'-monophosphate deaminase inhibitors Advances in Experimental Medicine and Biology. 431: 849-852. PMID 9598183  0.265
2013 Ye XM, Konradi AW, Sun M, Yuan S, Aubele DL, Dappen M, Dressen D, Garofalo AW, Jagodzinski JJ, Latimer L, Probst GD, Sham HL, Wone D, Xu YZ, Ness D, et al. Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 996-1000. PMID 23312944 DOI: 10.1016/J.Bmcl.2012.12.039  0.249
2011 Aubele DL, Truong AP, Dressen DB, Probst GD, Bowers S, Mattson MN, Semko CM, Sun M, Garofalo AW, Konradi AW, Sham HL, Zmolek W, Wong K, Goldbach E, Quinn KP, et al. Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 5791-4. PMID 21885276 DOI: 10.1016/J.Bmcl.2011.08.008  0.248
2010 Truong AP, Aubele DL, Probst GD, Neitzel ML, Semko CM, Bowers S, Dressen D, Hom RK, Konradi AW, Sham HL, Garofalo AW, Keim PS, Wu J, Dappen MS, Wong K, et al. Corrigendum to “Design, synthesis, and structure–activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline γ-secretase inhibitors” [Bioorg. Med. Chem. Lett. 19 (2009) 4920] Bioorganic & Medicinal Chemistry Letters. 20: 7553. DOI: 10.1016/J.Bmcl.2010.10.090  0.248
2013 Probst G, Aubele DL, Bowers S, Dressen D, Garofalo AW, Hom RK, Konradi AW, Marugg JL, Mattson MN, Neitzel ML, Semko CM, Sham HL, Smith J, Sun M, Truong AP, et al. Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch. Journal of Medicinal Chemistry. 56: 5261-74. PMID 23713656 DOI: 10.1021/Jm301741T  0.244
2009 Truong AP, Aubele DL, Probst GD, Neitzel ML, Semko CM, Bowers S, Dressen D, Hom RK, Konradi AW, Sham HL, Garofalo AW, Keim PS, Wu J, Dappen MS, Wong K, et al. Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 4920-3. PMID 19660943 DOI: 10.1016/J.Bmcl.2009.07.092  0.234
2000 Kasibhatla SR, Bookser BC, Probst G, Appleman JR, Erion MD. AMP deaminase inhibitors. 3. SAR of 3-(carboxyarylalkyl)coformycin aglycon analogues Journal of Medicinal Chemistry. 43: 1508-1518. PMID 10780907 DOI: 10.1021/jm990448e  0.23
2013 Bowers S, Xu YZ, Yuan S, Probst GD, Hom RK, Chan W, Konradi AW, Sham HL, Zhu YL, Beroza P, Pan H, Brecht E, Yao N, Lougheed J, Tam D, et al. Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates. Bioorganic & Medicinal Chemistry Letters. 23: 2181-6. PMID 23465612 DOI: 10.1016/j.bmcl.2013.01.103  0.227
2009 Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DW, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, et al. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. Bioorganic & Medicinal Chemistry Letters. 19: 6386-91. PMID 19811916 DOI: 10.1016/j.bmcl.2009.09.061  0.225
2010 Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, Tóth G, et al. Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorganic & Medicinal Chemistry Letters. 20: 4789-94. PMID 20634069 DOI: 10.1016/j.bmcl.2010.06.112  0.21
2011 Bowers S, Truong AP, Jeffrey Neitz R, Hom RK, Sealy JM, Probst GD, Quincy D, Peterson B, Chan W, Galemmo RA, Konradi AW, Sham HL, Tóth G, Pan H, Lin M, et al. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. Bioorganic & Medicinal Chemistry Letters. 21: 5521-7. PMID 21813278 DOI: 10.1016/j.bmcl.2011.06.100  0.209
2009 Bowers S, Probst GD, Truong AP, Hom RK, Konradi AW, Sham HL, Garofalo AW, Wong K, Goldbach E, Quinn KP, Sauer JM, Wallace W, Nguyen L, Hemphill SS, Bova MP, et al. N-Bridged bicyclic sulfonamides as inhibitors of gamma-secretase. Bioorganic & Medicinal Chemistry Letters. 19: 6952-6. PMID 19879755 DOI: 10.1016/j.bmcl.2009.10.060  0.206
2009 Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorganic & Medicinal Chemistry Letters. 19: 2179-85. PMID 19297154 DOI: 10.1016/j.bmcl.2009.02.111  0.195
2010 Truong AP, Tóth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorganic & Medicinal Chemistry Letters. 20: 6231-6. PMID 20833041 DOI: 10.1016/j.bmcl.2010.08.102  0.186
2011 Probst GD, et al. ea. ChemInform Abstract: Design of an Orally Efficient Hydroxyethylamine (HEA) BACE-1 Inhibitor (I) in a Preclinical Animal Model. Cheminform. 42: no-no. DOI: 10.1002/chin.201107120  0.178
2013 Mondal K, Regnstrom K, Morishige W, Barbour R, Probst G, Xu YZ, Artis DR, Yao N, Beroza P, Bova MP. Thermodynamic and kinetic characterization of hydroxyethylamine β-secretase-1 inhibitors. Biochemical and Biophysical Research Communications. 441: 291-6. PMID 24070613 DOI: 10.1016/j.bbrc.2013.09.081  0.119
2022 Ma S, Tang T, Probst G, Konradi A, Jin C, Li F, Silvio Gutkind J, Fu XD, Guan KL. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER breast cancer. Nature Communications. 13: 1061. PMID 35217640 DOI: 10.1038/s41467-022-28691-0  0.116
2012 Probst G, Xu YZ. Small-molecule BACE1 inhibitors: A patent literature review (2006 - 2011) Expert Opinion On Therapeutic Patents. 22: 511-540. PMID 22512789 DOI: 10.1517/13543776.2012.681302  0.112
2015 Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, et al. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Molecular Pharmaceutics. 12: 3986-98. PMID 26393951 DOI: 10.1021/Acs.Molpharmaceut.5B00432  0.096
1992 Weidmann P, Frank J, Graf W, Hausammann R, Heuberger T, Kerkhoven P, Probst G, Schudel P, Steinbach C, Müller A. [Monotherapy with the ACE-inhibitor ramipril or the calcium antagonist nitrendipine in essential hypertension]. Schweizerische Medizinische Wochenschrift. 122: 1497-503. PMID 1411408  0.081
2007 Tóth G, Bowers SG, Truong AP, Probst G. The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance. Current Pharmaceutical Design. 13: 3476-93. PMID 18220785 DOI: 10.2174/138161207782794284  0.062
2012 Justice SS, Li B, Downey JS, Dabdoub SM, Brockson ME, Probst GD, Ray WC, Goodman SD. Aberrant community architecture and attenuated persistence of uropathogenic Escherichia coli in the absence of individual IHF subunits. Plos One. 7: e48349. PMID 23133584 DOI: 10.1371/journal.pone.0048349  0.059
1986 Probst G, Michos N. Open clinical study with suprofen drops in the treatment of postoperative and posttraumatic pain Arzneimittel-Forschung/Drug Research. 36: 1107-1109. PMID 3768081  0.059
2014 Peine KJ, Guerau-de-Arellano M, Lee P, Kanthamneni N, Severin M, Probst GD, Peng H, Yang Y, Vangundy Z, Papenfuss TL, Lovett-Racke AE, Bachelder EM, Ainslie KM. Treatment of experimental autoimmune encephalomyelitis by codelivery of disease associated Peptide and dexamethasone in acetalated dextran microparticles. Molecular Pharmaceutics. 11: 828-35. PMID 24433027 DOI: 10.1021/Mp4005172  0.05
2000 Scholze J, Probst G, Bertsch K. Valsartan alone and in combination with hydrochlorothiazide in general practice. Results from two postmarketing surveillance studies involving 54,928 patients with essential hypertension Clinical Drug Investigation. 20: 1-7.  0.043
1999 Bauer H, Stelzhammer W, Fuchs R, Weiger TM, Danninger C, Probst G, Krizbai IA. Astrocytes and neurons express the tight junction-specific protein occludin in vitro Experimental Cell Research. 250: 434-438. PMID 10413597 DOI: 10.1006/excr.1999.4558  0.025
Hide low-probability matches.